PRESS RELEASE – 09.18.2026

Interim dividend for 2026

Schedule

As announced in a press release dated July 30, 2026, Wendel intends to pay an interim dividend of €2.55 per share as part of the dividend to be distributed for the 2026 financial year. The expected payment schedule is as follows:

  • ex-dividend date: November 17, 2026
  • record date: November 18, 2026
  • payment date: November 19, 2026

The balance of the dividend to be distributed for the 2026 financial year will be submitted for approval at the next Shareholders’ Meeting, to be held on May 27, 2027.

À propos de Wendel

Wendel SE est l’une des toutes premières sociétés d’investissement cotées en Europe. Dans le cadre de son activité d’investissement pour compte propre, elle investit dans des sociétés leaders dans leur secteur : ACAMS, Bureau Veritas, Crisis Prevention Institute, Globeducate, IHS Towers, Scalian, Stahl et Tarkett. En 2023, Wendel a annoncé son intention de développer une plateforme de gestion d’actifs privés pour compte de tiers en complément de ses activités d’investissement pour compte propre. Dans ce cadre, Wendel a finalisé les acquisitions d’une participation de 51 % dans IK Partners en mai 2024, de 72 % de Monroe Capital en mars 2025 et de 64 % (incluant la vente à terme) de Committed Advisors en avril 2026. Au 30 juin 2026, le Groupe gère 48,7 Mds d’euros pour le compte d’investisseurs tiers pro forma de l’acquisition de Committed Advisors, et environ 3,6 Mds d’euros (pro forma des cessions de Stahl et IHS) investis pour compte propre.

Wendel est cotée sur l’Eurolist d’Euronext Paris.

Notation attribuée par Standard & Poor’s : Long terme : BBB avec perspective stable — Court terme : A-2

Wendel est le Mécène Fondateur du Centre Pompidou-Metz. En raison de son engagement depuis de longues années en faveur de la Culture, Wendel a reçu le titre de Grand Mécène de la Culture en 2012.

Pour en savoir plus : wendelgroup.com

Suivez-nous sur LinkedIn @Wendel 

  

Press contacts  Analyst and investor contacts
Christine Anglade: +33 6 14 04 03 87          Olivier Allot: +33 1 42 85 63 73
c.anglade@wendelgroup.com o.allot@wendelgroup.com
   
Caroline Decaux: +33 1 42 85 91 27              Lucile Roch: +33 1 42 85 63 72
c.decaux@wendelgroup.com    l.roch@wendelgroup.com
   
Primatice  
Olivier Labesse: +33 6 79 11 49 71  
olivierlabesse@primatice.com  
Hugues Schmitt: +33 6 71 99 74 58  
huguesschmitt@primatice.com  

Attachment

Alphen aan den Rijn – September 18, 2026 – Wolters Kluwer, a global leader in information solutions, software and services, announces today that it has completed the reduction in share capital approved by shareholders at the Annual General Meeting of Shareholders held on May 21, 2026.

The company confirms that 7,800,000 ordinary shares held in treasury have now been cancelled. The total number of issued ordinary shares is therefore reduced to 224,716,153 (previously 232,516,153).

Following this cancellation, the number of shares held in treasury is now 2,276,510 and, in accordance with regulatory requirements, Wolters Kluwer has notified the Dutch Authority for the Financial Markets (AFM) of the change in its issued share capital and that it currently holds 1.01% of total issued ordinary shares.

Shares repurchased by the company are added to and held as treasury shares, to be used for capital reduction purposes through share cancellation. Part of these treasury shares may be retained and used to meet future obligations under share-based incentive schemes.

# # #

Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.  Wolters Kluwer reported 2025 annual revenues of €6.1 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,100 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX, Euro Stoxx 50, and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.

Media Investors/Analysts
Marnie Kontovraki Meg Geldens
Director Vice President
Global Communications Investor Relations
press@wolterskluwer.com ir@wolterskluwer.com
   

 

Forward-looking Statements and Other Important Legal Information
This report contains forward-looking statements. These statements may be identified by words such as “expect”, “should”, “could”, “shall” and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer’s businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Elements of this press release contain or may contain inside information about Wolters Kluwer within the meaning of Article 7(1) of the Market Abuse Regulation (596/2014/EU). Trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various co

Attachment

PASCAGOULA, Miss., Sept. 18, 2026 (GLOBE NEWSWIRE) — HII’s (NYSE: HII) Ingalls Shipbuilding division’s Virtual Reality (VR) Welding Lab has officially surpassed 1,000 trainees since opening in January 2025. The milestone highlights the impact of Ingalls’ investment in advanced training technology and the collaborative support of the U.S. Navy, AccelerateMS and Mississippi Gulf Coast Community College (MGCCC) which helped establish the facility.

The VR Welding Lab integrates immersive simulations into Ingalls’ established welding certification process, enabling new and experienced shipbuilders up to 10 times more hands-on practice in a safe and controlled environment.

“By leveraging immersive technology, we’re ensuring our shipbuilders enter the workforce with stronger, more consistent welding fundamentals,” said Anna Bourdais, director of the Maritime Training Center of Excellence at Ingalls Shipbuilding. “Our collaboration with the U.S. Navy and regional workforce partners is key to making these investments successful and we’re already seeing improvements in our Ingalls-trained shipbuilders.”

The milestone highlights the value of Mississippi’s statewide workforce partnerships when they align with industry needs in order to expand high-quality training opportunities, which align with industry needs. By combining federal support, state workforce investment and community college instruction with Ingalls’ expertise in shipbuilding and skilled-trades development, this partnership delivers a scalable, industry-aligned program that strengthens Mississippi’s workforce pipeline and supports long-term economic resilience across the region.

VR Welding Photos_RH_June 30, 2026_Olivia

A photo accompanying this release is available at: http://hii.com/news/ingalls-shipbuildings-virtual-reality-welding-lab-surpasses-1000-trainees/.

Shipbuilders who complete the VR program report immediate improvements in welding technique, confidence and readiness for certification. Welding Apprentice Olivia Saranthus says the VR training has already made a noticeable difference in her skill development.

“I had never welded before, but the VR system helped me learn, improve my technique and clearly see where I needed to get better. It’s given me a lot more confidence,” Saranthus said. “Even though I am still in training, I can already see my welds getting better, and the extra practice has helped me move through my certifications much faster.”

AccelerateMS, a statewide workforce and economic program and a key funding partner for the VR initiative, underscored how modern training tools strengthen Mississippi’s workforce pipeline.

“Our partnership with Ingalls Shipbuilding demonstrates exactly what we aim to accomplish across the state, focusing on funding modern, scalable workforce solutions that open doors for Mississippians,” said Courtney Taylor, executive director of AccelerateMS. “Ingalls is setting a national example of how advanced training tools can transform both learning outcomes and career opportunities.”

As demand for highly skilled craft workers continues to grow, Ingalls has plans to continue expanding access to VR welding and pursue additional VR-based training opportunities across other trades. The VR welding program remains a cornerstone of Ingalls’ workforce development strategy, supporting new hires, apprentices and experienced craftsmen as they build and deliver the critical ships our U.S. Navy needs.

To learn more about careers and training opportunities at HII’s Ingalls Shipbuilding division, visit HII.com/careers.

About HII

HII is America’s largest shipbuilder, delivering the world’s most powerful ships and all-domain mission technologies, including unmanned systems, to U.S. and allied defense customers. HII is the largest producer of unmanned underwater vehicles for the U.S. Navy and the world.

With a more than 140-year history of advancing U.S. national security, HII builds and integrates defense capabilities extending from the core fleet to C6ISR, AI/ML, EW and synthetic training. Headquartered in Virginia, HII’s workforce is 45,000 strong. For more information, visit:

Contact:
Kimberly K. Aguillard
Kimberly.K.Aguillard@hii-co.com
228-355-5663

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ca912610-1eb4-4480-b024-ed487d262b66

FORM 8.5 (EPT/RI)

Amendment Sec 2(a)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Tribal Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor and Joint Broker to Tribal Group Plc
(d)        Date dealing undertaken: 17th September 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales

Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

Ordinary shares

Purchase

5791

81.4 81.4

Ordinary shares

Sales

9,379

81.4 81.4

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 18th September 2026
Contact name: Priyali Bhattacharjee
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

New gated community offers luxury townhomes close to beaches, shopping, and dining

ESTERO, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the opening of its newest Southwest Florida community, Summercrest by Toll Brothers, in Estero, Florida. This new gated community offers luxury townhomes with access to vibrant amenities and a prime location near Gulf Coast beaches, shopping, and dining.

Summercrest by Toll Brothers showcases a variety of stylish townhome designs with open-concept floor plans ranging from approximately 1,944 to 2,495 square feet. Homes feature 3 bedrooms, 2.5 baths, versatile loft spaces, covered lanais, and options for flex rooms and offices. Select homes offer first-floor primary bedroom suites, two-story great rooms, and two-car garages. Pricing begins in the mid-$500,000s.

Summercrest by Toll Brothers

“Summercrest by Toll Brothers is the perfect blend of low-maintenance living and luxury design, all within a location that offers convenience and access to Florida’s best beaches, shopping, and recreation,” said Sean Walsh, Division President of Toll Brothers in Southwest Florida. “We are excited to offer home shoppers the opportunity to tour our new community and find their dream home in Estero.”

Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The state-of-the-art Design Studio allows home shoppers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants.

Future amenities at Summercrest are designed for wellness and relaxation, including a sparkling pool, spa, clubhouse, and fitness center. Residents will enjoy easy access to Coconut Point, Miromar Outlets, Bonita Springs beaches, and major transportation routes including Interstate 75.

The Sales Center is now open at 21254 Estiva Villa Circle in Estero. For more information on Summercrest by Toll Brothers, visit TollBrothers.com/FL or call 844-551-2787.

About Toll Brothers

Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded in 1967 and became a public company in 1986 with common stock listed on the New York Stock Exchange under the symbol “TOL.” Toll Brothers builds new homes and communities in over 60 markets across the United States, serving first-time, move-up, active-adult, and second-home buyers. The Company also operates its own architectural, engineering, mortgage, title, land development, smart home technology, landscape, and building components manufacturing businesses.

Toll Brothers was named the #1 Most Admired Home Builder in Fortune magazine’s 2026 list of the World’s Most Admired Companies®, the ninth year the Company has achieved this honor. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com.

From Fortune, ©2026 Fortune Media IP Limited. All rights reserved. Used under license.

Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | ameck@tollbrothers.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ef0d6fe4-3070-4809-b780-b1cebd3baf98

Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)

District Court Lifts Automatic Stay and Resolves All Legacy Debt-Related Legal Proceedings as Settlement Settles Approximately $61 Million in Pre-Petition Debt (100% Thereof); $7 Million in New Capital Committed; Company Emerges with a Fortified Balance Sheet and Sharpened Focus on Growth

TEL AVIV, Israel, Sept. 18, 2026 (GLOBE NEWSWIRE) — Gauzy Ltd. (Nasdaq: GAUZ) (“Gauzy” or the “Company”), a global leader in light and vision control technology, today announced a critical resolution to its balance sheet: the Tel Aviv-Jaffa District Court (the “Court”) has granted final approval, effective September 8, 2026, of the Company’s comprehensive debt settlement (the “Settlement”) under Israel’s Insolvency and Economic Rehabilitation Law, 5758-2018, in Insolvency Proceeding No. 51175-03-26. The decision draws a definitive line under a legacy capital structure and clears the way for Gauzy to operate as a debt-settled, well-capitalized public company squarely focused on its core Smart Glass business.

Settlement Highlights

  • Overwhelming Creditor Mandate: Creditors representing 98.96% of voting claims across every class voted in favor of the Settlement — including 100% of the Company’s secured lenders, OIC Investment Agent LLC and Bank Mizrahi-Tefahot Ltd. — reflecting near-unanimous support for management’s restructuring plan.
  • Approximately $61 Million of Legacy Debt Fully and Finally Resolved: The Settlement, court-confirmed on September 8, 2026, resolves substantially all of the Company’s pre-petition liabilities — secured, employee, institutional-priority and general unsecured claims alike — under a single, court-sanctioned structure.
  • $7 Million of New Equity Capital Committed: The Company has received a binding commitment for a $7 million equity investment (PIPE) led by management as a part of the court approved Settlement.  The PIPE is intended to fund immediate working capital, professional fees and priority employee obligations, and putting the Settlement on a fully-financed footing.
  • Insolvency Stay Lifted; Legacy Legal Matters Resolved; Balance Sheet De-Risked: With final Court approval now obtained, the automatic stay under Israeli insolvency law has been lifted, all legacy debt claims, executions and legal proceedings against the Company have been resolved, settled or withdrawn, and the Company’s previously scattered secured claims are being consolidated into a single, unified security structure administered by the Settlement trustees, which will be released in full as the Company completes its repayment obligations.

An Overwhelming Mandate from Every Class of Creditor

As previously, announced, the Settlement was put to a vote of the Company’s creditors at a meeting convened under the supervision of the Official Receiver and Insolvency Commissioner, following extensive negotiation among the Company, its secured lenders, its employees, and its general creditor base. The result was decisive: 98.96% of voting claims, across all classes, were cast in favor — anchored by unanimous, 100% approval from the Company’s secured lending group. Management views this outcome as a powerful vote of confidence in Gauzy’s underlying business, its technology leadership, and the credibility of the go-forward plan negotiated with the Settlement trustees, Adv. Ehud Gindes and Adv. (CPA) Simion Keidar.

Creditor Class Approval Vote
Secured lenders (OIC Investment Agent LLC and Bank Mizrahi-Tefahot Ltd.) Approved
Employees Approved
Priority institutional creditors Approved
General unsecured creditors Approved
All classes, combined 98.96%
   

Resolution of Approximately $61 Million in Legacy Liabilities

The Settlement addresses the full spectrum of the Company’s pre-petition capital structure. In the aggregate, approximately $61 million of legacy liabilities — accumulated obligations to secured lenders, employees, Israeli governmental institutions, and general trade and other unsecured creditors in Israel, the United States and Germany — are resolved under the Settlement, replacing a fragmented, contested debt stack with a single, court-approved, fully consensual arrangement. Amounts below are approximate and rounded, consistent with the Settlement documentation, and remain subject to final adjudication of debt claims by the Settlement trustees.

Legacy Liability Component Amount % of Total
Secured claims (OIC Investment Agent LLC and Bank Mizrahi-Tefahot Ltd.) ~$48.0 million ~79%
Employee claims (priority) ~$4.0 million ~7%
Priority claims to Israeli governmental institutions ~$2.9 million ~5%
General unsecured claims (Israel, U.S. and Germany) ~$5.5 million ~9%
Total pre-petition liabilities resolved ~$61.0 million 100%
     

$7 Million of New Equity Capital and a Fortified Balance Sheet

To ensure the Settlement is fully financed from day one, Gauzy has received a binding commitment for $7 million of new equity capital through a private investment in public equity (PIPE) led by Chief Executive Officer Eyal Peso together with other investors aligned with management. Of the proceeds, up to $4 million is earmarked to promptly and fully satisfy the Company’s priority employee claims, with the balance funding working capital, professional costs of the Settlement process and general corporate purposes. The new equity capital places Gauzy’s near-term liquidity on a fully-funded basis independent of the legacy claims which will be settled in accordance with the terms of the debt settlement arrangement.

Insolvency Stay Lifted and Legacy Legal Proceedings Resolved

Final Court approval terminates the automatic stay of proceedings that had applied under Israel’s Insolvency and Economic Rehabilitation Law since the process began. As a result, all claims, executions, attachments and legal proceedings brought — or that could have been brought — against the Company in respect of its pre-petition liabilities have been fully and finally settled, resolved or withdrawn pursuant to the Settlement, and creditors bound by the Settlement are precluded from pursuing independent legal action in respect of such legacy claims outside its framework. Security interests that were previously held individually by the Company’s secured creditors are being consolidated into a single, unified security arrangement administered by the Settlement trustees to support the Company’s obligations under the new equity investment and repayment structure described below, and are to be released in full as the Company completes those obligations. The result is a Company that, for the first time in this process, is free to run its day-to-day operations, capital planning and customer commitments without the overhang of contested legacy claims or active creditor litigation.

Post-Settlement Ownership and Exit Value Participation

Upon completion of the related management buyout, Gauzy’s fully diluted share capital will be held as follows:

Post-Settlement Fully-Diluted Ownership Percentage
Management (via Management Buyout) 50%
Creditors (in respect of settled legacy claims) 20%
Existing shareholders (pre-Settlement holders) 30%
   

Beyond this initial allocation, the Settlement gives creditors a further source of recovery during the term of the Settlement: 70% of the net proceeds of any Exit Event (as defined in the Settlement, generally including a sale, merger or similar liquidity event) will be applied to the Settlement fund for the benefit of creditors, up to the amount then required to satisfy the Company’s outstanding obligations under the Settlement, with the remainder retained by the Company and/or its shareholders.

A Structured, Six-Year Path to Full Resolution

Beginning April 1, 2027, the Company will make monthly payments into the Settlement fund over a 72-month (six-year) period: $200,000 per month for the first 24 months, $250,000 per month for the following 24 months, and $300,000 per month for the final 24 months — aggregate nominal payments of approximately $18 million over the life of the Settlement — supplemented, as applicable, by Exit Event proceeds as described above. Priority employee claims of approximately $4 million are being satisfied promptly out of the new equity investment proceeds, ahead of this schedule.

Management Commentary

“A 99% creditor vote — with every single one of our secured lenders voting in favor — is about as close to unanimous as a restructuring gets, and it is a direct reflection of the trust our creditors, our employees, our shareholders and our secured lenders place in this Company and in where we are headed,” said Eyal Peso, Chief Executive Officer of Gauzy. “Legacy debt is behind us. Roughly $61 million of pre-petition claims are fully and finally resolved, every lien our secured lenders held is being folded into a single structure that unwinds as we pay it down, and every pending legacy legal proceeding is resolved. With $7 million of new equity capital committed and a capital structure our team, our creditors and our shareholders all now share in, we are turning one hundred percent of our attention back to what has always defined Gauzy: our core ADAS/CMS product range for commercial vehicles, and our state-of-the-art, industry-proven Smart Glass technologies for our world-class customers across automotive, aeronautics and architecture.”

“This outcome reflects month of disciplined, good-faith negotiation among the Company, its secured lenders, its employees and its broader creditor base,” said Adv. Ehud Gindes, joint court-appointed Settlement trustee. “A 99% vote in favor, anchored by unanimous support from the secured creditor class, gave the Court a clear and well-supported basis to grant final approval and to settle 100% of its outstanding debt.”

“Following intensive efforts by all parties involved, a comprehensive and balanced Settlement arrangement has been achieved. It provides creditors with tangible repayment sources, meaningful equity participation, and a share in the Company’s future value, while supporting the Company’s continued operations and rehabilitation. This outcome is designed to maximize creditor recoveries and preserve the Company’s employees, operations, and valuable assets,” said Adv. (CPA) Simion Keidar, joint court-appointed Settlement trustee.

Looking Ahead

With its legacy balance sheet resolved and new capital committed, Gauzy is sharpening its strategic focus on two core pillars: its ADAS/CMS (Advanced Driver-Assistance Systems and Camera Monitor Systems) product range for commercial vehicles, and its Smart Glass light and vision control technologies serving the automotive, aeronautics and architecture segments. The Company intends to concentrate its resources and go-to-market efforts on these core product lines, and on converting its existing order backlog and pipeline with global customers into revenue growth. The Company will continue to provide updates on its financial position and operating performance in its ongoing filings with the U.S. Securities and Exchange Commission (the “SEC”).

Separately, the Company’s French subsidiaries remain subject to ongoing court-supervised rehabilitation proceedings in France, including the appeals the Company filed against the decisions to open the rehabilitation proceedings and the decision to grant Vision Systems assets. Gauzy continues to work closely with the relevant stakeholders toward a successful exit from those proceedings, and believes the Settlement equips the Company with important tools to support that effort — including fresh capital and the opportunity to pledge assets held by its French subsidiaries to help fund a continuation plan for their business. The Company will provide a further update on the impact and developments regarding its French operations in due course.

About Gauzy
Gauzy Ltd. is a fully-integrated light and vision control company, focused on the research, development, manufacturing, and marketing of vision and light control technologies that support safe, sustainable, comfortable, and agile user experiences across various industries. Headquartered in Tel Aviv, Israel, the company has additional subsidiaries and entities based in Germany, France, the United States, Canada, China, Singapore, and the United Arab Emirates. Gauzy serves leading brands across aeronautics, automotive, and architecture in over 60 countries through direct fulfillment and a certified and trained distribution channel.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements include, without limitation, statements regarding the anticipated effects, benefits and long-term impact of the Settlement; the Company’s committed new equity investment and capital structure; the timing and amount of future payments under the Settlement; the release of security interests upon completion of the Company’s obligations; participation in any future Exit Event; the Company’s liquidity, ability to continue as a going concern, and future business, financial condition and results of operations; and the Company’s strategic priorities and growth plans. These statements are often identified by words such as “may,” “will,” “expect,” “anticipate,” “believe,” “estimate,” “intend,” “plan,” “continue,” “project,” “target,” “outlook” and similar expressions, or their negatives, though not all forward-looking statements contain these words. Such statements are based on management’s current expectations and beliefs and are subject to significant risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied, including, among others: the risk that actual claims ultimately allowed in the insolvency proceeding, or their treatment, may differ from current estimates; the Company’s ability to satisfy its payment and other obligations under the Settlement and the new equity investment arrangements over their respective terms; the occurrence (or non-occurrence) and timing of any Exit Event; the Company’s ability to maintain compliance with Nasdaq continued listing requirements; the Company’s ability to execute on its business strategy and convert backlog into revenue; competitive, technological and market developments affecting the smart glass, architecture, automotive, aviation and rail industries; general economic, financial and geopolitical conditions in Israel and the other jurisdictions in which the Company operates; and other risks and uncertainties described in the Company’s Annual Report on Form 20-F and in its other filings and furnishings with the SEC, including its reports on Form 6-K. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Investor & Media Contact:

Amanda Yevdaev, EVP Marketing
Gauzy Ltd.
PR@gauzy.com

Corporate Announcement no. 32/2026: Half-Year Report 1 January 2026  – 30 June 2026

Copenhagen, 18 September 2026

The Board of Directors and the Management have today discussed and approved the Half-Year Report of Ress Life Investments A/S for the period 1 January 2026 – 30 June 2026:

  • Ress Life Investments A/S realised a net profit after tax of USD 6,655,829 for the period 1 January 2026 – 30 June 2026. The net profit for the period corresponds to a net return on equity of 3.2%, an earnings per share of USD 57.34 and an increase in net asset value of USD 83.69 per share.
  • The period’s return was mainly driven by life expectancy updates, changes in discount rates, performance in the Legacy Portfolio, as well as the ageing of insureds and the resulting shortening of life expectancies, partly offset by administrative and staff costs. Profit for the 6-month period was on target.
  • The Company has entered into an agreement, through which a majority of policies are being sold to a market counterparty. The Company is entitled to a share of the future payouts of the disposed policies in an earnout agreement. The earnout agreement, valued at around 129 million USD as at June 30 2026, is included in the Company’s financial assets. The Company refers to corporate announcement no. 31/2026 with regard to a dispute arisen between the Company and the purchaser.
  • Equity stands at USD 225,446,310 as of 30 June 2026, corresponding to a net asset value of USD 2,722 per share compared with a net asset value of USD 2,639 at 31 December 2025.
  • During the period, 3,099 new ordinary shares were issued.
  • Management expects that the life settlements market will continue to offer attractive, diversified returns for the medium term.
  • The target net return for the Company is 7.0% in USD for 2026 and 10% for 2027 onwards. It is reasonable to assume that the yield on the underlying assets is sufficient to reach the target over the medium term.

Questions related to this announcement can be made to the Company’s AIF-manager, Finserve Nordic AB, Gustaf Hagerud, Gustaf.hagerud@finserve.se, telephone: +46 73 612 72 42 or to the Company’s Chairman Søren Andersen, email: soan@norli.dk.

Yours sincerely

Ress Life Investments A/S
The Board of Directors

Attachments

  • If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹
  • Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; safety was consistent with established Cosentyx profile²
  • Despite being a common inflammatory rheumatic disease in people over 50, there are limited advanced treatments for PMR; extended use of steroids is associated with poor outcomes³⁻⁷

Basel, September 18, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Cosentyx® (secukinumab) in polymyalgia rheumatica (PMR).⁸ The opinion supports Cosentyx use for treatment of PMR in adults who have had an inadequate response to steroids or who experience relapse during steroid taper.⁸ If approved, Cosentyx would be the first interleukin-17A (IL-17A) inhibitor approved in Europe for people living with PMR, a disease with very limited advanced treatment options.¹˒³⁻⁷

“The introduction of Cosentyx to the PMR space represents a major advancement for patients and clinicians, providing an effective treatment option while also reducing reliance on steroids – which can present challenges with long-term use,” said Prof Christian Dejaco, Director, Dept of Rheumatology, South Tyrol Health Trust, Bruneck, Italy. “I am encouraged by this positive CHMP opinion for a treatment which could both reduce flares and lower patients’ steroid exposure.”

The positive CHMP opinion is supported by results from the pivotal REPLENISH Phase III trial in which all primary and secondary endpoints were met across both Cosentyx 300mg and 150mg treatment arms, including complete sustained remission and time until patients needed additional treatment through week 52.² No new safety signals were identified in PMR patients receiving Cosentyx. The data were published in the New England Journal of Medicine and simultaneously presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress on June 3, 2026.²˒⁹

“People living with PMR need treatments that provide lasting remission, prevent relapses and are well-tolerated, in order to achieve the best possible long-term outcomes,” said Patrick Horber, M.D., President, International, Novartis. “Cosentyx is the first and only anti-IL-17A shown to provide sustained remission in patients with PMR, and its approval would represent an important step in transforming care for those living with this disease. Today’s positive opinion builds on the well-established impact of Cosentyx in autoimmune disease and could help establish a new standard of care for PMR in Europe.”

Following the CHMP recommendation for approval, the European Commission (EC) is expected to issue a final decision within approximately two months.

About Cosentyx
Cosentyx is a fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation underlying multiple immune-mediated inflammatory diseases. It is approved for use in adults with psoriatic arthritis (PsA), moderate to severe plaque psoriasis (PsO), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), and hidradenitis suppurativa (HS)¹⁰⁻¹². Cosentyx is also approved for use in pediatric patients, including those with PsO, juvenile idiopathic arthritis subtypes such as juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA), and in the U.S. for pediatric patients aged 12 years and older with moderate to severe HS and juvenile AS.¹⁰⁻¹⁷

About REPLENISH trial
The REPLENISH trial (NCT05767034) is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted across 27 countries, evaluating the efficacy and safety of Cosentyx in patients with polymyalgia rheumatica (PMR). Patients were randomized into three treatment arms: Cosentyx 300mg, Cosentyx 150mg, or placebo, all in combination with a 24-week steroid taper regimen. The primary endpoint of the trial was to assess whether Cosentyx 300mg s.c. plus a 24-week steroid taper is superior to placebo plus a 24-week steroid taper in achieving sustained remission at week 52. Key secondary endpoints included the proportion of patients achieving complete sustained remission at week 52, the adjusted annual cumulative steroid dose, and the time to first use of escape or rescue treatment through week 52.¹⁸

About polymyalgia rheumatica (PMR)
Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease in adults aged 50 years and older, typically characterized by acute pain and stiffness in the shoulders, neck, and hips.³ Relapses are frequent, affecting up to 40% of patients in the first year.⁵ Long-term steroid use is the current standard of care and carries significant risks, including osteoporosis and diabetes.¹⁹ Beyond physical complications, PMR substantially impairs quality of life through pain, fatigue, restricted mobility, and fear of relapse.⁵˒²⁰˒²¹

About Novartis Immunology
At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with complex, and often overlooked autoimmune and immune-mediated diseases, so they can reclaim their lives. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

  1. European Medicines Agency. Search results for “polymyalgia rheumatica.” European Medicines Agency. https://www.ema.europa.eu/en/search?search_api_fulltext=polymyalgia%20rheumatica. Accessed September 11, 2026.
  2. Stone JH, Buttgereit F, Saraux A, et al. Secukinumab in polymyalgia rheumatica. New England Journal of Medicine. 2026. doi:10.1056/NEJMoa2602567. https://www.nejm.org/doi/full/10.1056/NEJMoa2602567.
  3. Espígol-Frigolé G, Dejaco C, Mackie SL, Salvarani C, Matteson EL, Cid MC. Polymyalgia rheumatica. The Lancet. 2023;402(10411):1459–1472. doi:10.1016/S0140-6736(23)01310-7. https://doi.org/10.1016/S0140-6736(23)01310-7.
  4. Gabriel SE, Sunku J, Salvarani C, O’Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis & Rheumatism. 1997;40(10):1873-1878.
  5. Floris A, Piga M, Chessa E, et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clinical Rheumatology. 2022;41(1):19-31. DOI: 10.1007/s10067-021-05819-z.
  6. Regeneron Pharmaceuticals, Inc.; Sanofi. Kevzara® (sarilumab) injection, for subcutaneous use: US prescribing information. Revised June 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761037s013lbl.pdf. Accessed September 11, 2026.
  7. European Medicines Agency. Kevzara: EPAR product information [April 25, 2022]. https://www.ema.europa.eu/en/documents/product-information/kevzara-epar-product-information_en.pdf. Accessed September 11, 2026.
  8. European Medicines Agency (EMA). Cosentyx, INN-secukinumab: CHMP post-authorisation summary of positive opinion. European Medicines Agency; 2026. Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cosentyx-vr-0000326984_en.pdf. Accessed September 18, 2026.
  9. Dejaco C, et al. Secukinumab in polymyalgia rheumatica: Results of the phase 3 REPLENISH trial. Oral Presentation #OP0116. Presented at: European Congress of Rheumatology (EULAR) 2026; June 3-6, 2026; London, UK.
  10. Novartis Europharm Limited. Cosentyx® (secukinumab): Summary of Product Characteristics. Available at: Cosentyx, INN-secukinumab [Last accessed: May 2026].
  11. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. British Journal of Dermatology. 2012;167(4):717-724. doi:10.1111/j.1365-2133.2012.11099.x.
  12. Novartis Cosentyx shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-clinically-meaningful-symptom-improvements-patients-hidradenitis-suppurativa-pivotal-phase-iii-trials [Last accessed: May 2026].
  13. Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis [Press release]. Available at:  https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-moderate-severe-plaque-psoriasis [Last accessed: May 2026].
  14. Novartis Cosentyx receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-enthesitis-related-arthritis-and-psoriatic-arthritis [Last accessed: May 2026].
  15. Novartis Cosentyx receives positive CHMP opinion for expanded use in childhood arthritic conditions. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-secukinumab-receives-positive-chmp-opinion-expanded-use-childhood-arthritic-conditions [Last accessed: May 2026].
  16. Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa. [Press release]. Available at:https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-pediatric-patients-aged-12-moderate-severe-hidradenitis-suppurativa [Last accessed: May 2026].
  17. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.
  18. ClinicalTrials.gov. Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) (REPLENISH). Identifier NCT05767034 [June 22, 2026]. https://clinicaltrials.gov/study/NCT05767034. Accessed September 11, 2026
  19. Mazzantini M, Torre C, Miccoli M, Baggiani A, Talarico R, Bombardieri S, Di Munno O. Adverse Events During Longterm Low-dose Glucocorticoid Treatment of Polymyalgia Rheumatica: A Retrospective Study. Journal of Rheumatology. 2012;39(3):552-557. doi:10.3899/jrheum.110851.
  20. Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B, Choy EHS, Scott DGI, Hazleman BL, Bourke B, Gendi N, Dasgupta B. Clinical Outcomes, Quality of Life, and Diagnostic Uncertainty in the First Year of Polymyalgia Rheumatica. Arthritis & Rheumatism. 2007;57(5):803-809.
  21. Mackie SL, Arun P, Padmanabhan V, Arjona A, Kullman JA. Patient perspectives on life impact and unmet needs in giant cell arteritis and polymyalgia rheumatica: insights from social media. Rheumatol Adv Pract. 2026;10(1):rkaf140. doi:10.1093/rap/rkaf140.

# # #

Novartis Media Relations
E-mail: media.relations@novartis.com

 

 
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
 

Zurich, Friday, September 18, 2026 – Lufthansa has been named “World’s Best First Class Onboard Dining” at the 2026 Skytrax World Airline Awards, underscoring the strength of its partnership with gategourmet Germany and the successful launch of its groundbreaking Future Onboard Experience (FOX) program.

As Lufthansa’s strategic catering and hospitality partner, gategourmet Germany played a central role in developing and implementing the award-winning First Class dining experience, working side-by-side with Lufthansa and renowned two-Michelin-star chef Christoph Kunz over more than two years to create a new benchmark for fine dining at 35,000 feet.

“Congratulations to Lufthansa on this prestigious recognition in its centenary year. We are proud to have partnered with Lufthansa on the Future Onboard Experience (FOX), helping bring a bold vision for premium hospitality to life. This award reflects Lufthansa’s commitment to excellence and the dedication of the Lufthansa and gategourmet Germany teams, supported by 2-Michelin Star chef Christoph Kunz, creating a new benchmark for First Class dining. We look forward to continuing our journey together to elevate the travel experience for guests around the world.” said Herman Anbeek, President Europe, gategroup.

Olaf Mauthe, Senior Director Hospitality & Catering Management, Lufthansa Airlines, said: “The success of our new First Class culinary concept is the result of a true partnership. Together with gategourmet Germany and Chef Christoph Kunz, we challenged conventional approaches to inflight dining and developed a concept that brings two-Michelin-star restaurant-quality hospitality to 35,000 feet. We are proud to see this effort recognized by travelers around the world.”

From Michelin-Starred Restaurant to 35,000 Feet

As part of Lufthansa’s Future Onboard Experience (FOX), the airline’s transformation of its onboard experience, gategourmet Germany introduced Chef Christoph Kunz as a culinary partner for Lufthansa’s new First Class concept and helped translate his Michelin-starred philosophy into an award-winning inflight dining experience.

The development process brought together Lufthansa’s culinary team, Chef Kunz, and gategourmet experts led by Christoph Brandstätter, Regional Executive Chef Central Europe and Max Herzog, Senior Executive Chef for the Lufthansa Group. Through culinary workshops, tastings, and numerous test flights, the teams refined and optimized the concept before its launch across Lufthansa’s First Class network.

A Culinary Center of Excellence in Germany

To support the new First Class concept, gategourmet Germany established a dedicated team of chefs with backgrounds in Michelin-starred and fine-dining restaurants.

Today, Lufthansa First Class departures from Frankfurt and Munich benefit from highly trained culinary teams and rigorous quality controls that ensure consistency, precision, and product excellence.

The result is a dining experience that successfully translates two-star gastronomy into a large-scale airline operation while maintaining the standards expected by Lufthansa’s most discerning guests.

Raising the Standard of Airline Dining

Introduced in March 2026, the new First Class dining concept was built around greater choice, personalization, and elevated presentation. The collaboration encompassed the full spectrum of the onboard culinary experience, including menu development, service concepts, operational processes, customer testing and onboard equipment. Complementing the culinary offering, deSter, a gategroup brand, developed the FOX serviceware and equipment concept, balancing premium design, operational efficiency, and sustainability.

The recognition highlights the strength of the partnership between Lufthansa and gategroup and reinforces gategroup’s role as a trusted innovation partner for leading airlines worldwide.

About gategroup

gategroup is the leading global provider of airline catering, retail-on-board, and hospitality products and services. Headquartered in Zurich, Switzerland, the company serves millions of passengers through a network of nearly 300 locations in more than 68 countries. By leveraging innovation and operational expertise, gategroup partners with the world’s leading airlines to create exceptional travel experiences. Learn more at www.gategroup.com

mediacontact@gategroup.com

  • Second consecutive year and tenth time the airline has taken home this honour since 2010
  • Airline also wins World’s Best Business Class Lounge Dining for the Air Canada Signature Suite in Toronto for the third consecutive year
  • Other honours include Best Cabin Crew in Canada and Best Economy On Board Catering in North America

MONTRÉAL, Sept. 18, 2026 (GLOBE NEWSWIRE) — Air Canada today was named the Best Airline in North America at the 2026 Skytrax World Airline Awards for the second year in a row. It represents the tenth time Air Canada has received this honour since 2010. Presented this year in London, UK, the Skytrax awards, which are based on customer satisfaction surveys of millions of global travellers, also recognized once again the Toronto Air Canada Signature Suite as the World’s Best Business Class Lounge Dining for the third straight year. Air Canada also took home additional honours for Best Cabin Crew in Canada, Best Economy On Board Catering in North America and Best Business Class Lounge in North America.

Air Canada Named Best Airline in North America at the 2026 Skytrax World Airline Awards

Air Canada also moved up two spots and ranks 17th among the World’s Top 100 Airlines in 2026, the only North American carrier to make top 20.

“We’re incredibly proud to be named Best Airline in North America. On behalf of 40,000 Air Canada coworkers around the world, we thank our customers for their trust, loyalty, and for choosing to fly with us. Their recognition is especially meaningful because it reflects the views of the people who experience our products and services firsthand. This award belongs to our people, whose professionalism, dedication, and genuine care for our customers make moments of exceptional hospitality possible across our global network. I’m honoured to accept this recognition on their behalf and thank them for their commitment to elevating the customer experience,” said Mark Nasr, Executive Vice President & Chief Operations Officer at Air Canada.

These awards recognize Air Canada’s leadership in the industry and its continued commitment to enhancing every stage of the travel journey, as recognized by customers worldwide. Over the past several years, the airline has introduced fast, free Wi-Fi sponsored by Bell, a mobile app that is an industry reference with its expanded functionality, complimentary premium snacks, wine and beer on all flights, and additional content on its award-winning in-flight entertainment system. Air Canada has also invested in new and upgraded lounges, streamlined airport processes, its award-winning Aeroplan loyalty program, and seamless intermodal travel options that allow customers to book air and ground transportation on a single ticket. Earlier this year, the airline also introduced the next generation of its cabin design with the entry into service of the Airbus A321XLR. The Glowing Hearted design delivers a distinctly Canadian experience, emphasizing comfort, care, and connection for all customers on every flight.

About the Air Canada Signature Suite 

Air Canada presents two Signature Suite lounges for departing international customers at Toronto Pearson and Vancouver International airports. Recognized by the Skytrax World Airline Awards for the World’s Best Business Class Lounge Dining at the Air Canada Signature Suite at Toronto Pearson, our menu showcases Canada’s diverse ingredients through refined, locally inspired dishes that evolve with the seasons. The experience is complemented by a curated wine list featuring standout Canadian and international labels, emphasizing craftsmanship and the unique character of Canada’s wine regions. Our cocktail menu, crafted with premium ingredients and creative flair, draws from global trends to deliver a memorable, elevated experience. Designed to evoke a Canadian sense of place, each Signature Suite reflects the beauty, warmth, and sophistication of the country it represents.

About the Skytrax World Airline Awards 

The World Airline Awards are wholly independent and impartial, introduced in 1999 to provide a customer satisfaction study that is truly global. Travellers across the world vote in the largest airline passenger satisfaction survey to determine the award winners. The awards are referred to by media around the world as “the Oscars of the aviation industry”. Skytrax pay all costs of the Survey and Awards process, with no sponsorship. There is no survey entry or registration fee, and awards event is free to attend and there are no charges or royalty payments for use of the award logos and results. The online survey operated from September 2025 to August 2026, and more than 100 customer nationalities participated. All survey entries were screened to identify IP and user information, with duplicate, suspect and ineligible entries deleted. Over 300 airlines are featured in the 2025/2026 survey results. The customer survey was offered in English, French, Portuguese, Spanish, Turkish, Chinese, Japanese and Korean.

About Air Canada

Air Canada is Canada’s largest airline, the country’s flag carrier and a founding member of Star Alliance, the world’s most comprehensive air transportation network. Headquartered in Montréal, Air Canada provides scheduled service directly to more than 180 airports in Canada, the United States and internationally on six continents. It holds a Four-Star ranking from Skytrax. Air Canada’s Aeroplan program is Canada’s premier travel loyalty program, with more than 10 million members worldwide. Members can earn or redeem points on the world’s largest airline partner network of more than 50 airlines, plus through an extensive range of merchandise, hotel and car rental partners. Through Air Canada Vacations, it offers a selection of vacation and Flight & Hotel packages, tours, cruises, car rentals, and experiences. Its freight division, Air Canada Cargo, provides air freight lift and connectivity to hundreds of destinations across six continents using Air Canada’s passenger and freighter aircraft. Air Canada’s climate-related ambition includes a long-term aspirational goal of net-zero greenhouse gas emissions by 2050. For additional information, please see Air Canada’s TCFD disclosure. Air Canada shares are publicly traded on the TSX (AC).

Contacts:        media@aircanada.ca

Internet:        aircanada.com/media

Read our annual report Here

Sign up for Air Canada news: aircanada.com

Media Resources:
Photos
Videos
B-Roll
Articles

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dc0f0834-74c4-4ae4-86e5-74d1d9509ad3

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.